David Cahn, DO
Payments from drug & device makers
Across 469 payments — averaging $67.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Pfizer$8K
- Janssen Scientific Affairs, LLC$5K
- Dendreon Pharmaceuticals LLC$1K
- Novartis$1K
- Bayer$839
- plus $8K from 35 others
What the payments were for
- Consulting fees$19,60162%
- Speaking & faculty fees$5062%
- Food & beverage$11,27936%
- Education$1611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 5 | $8,359 |
| Pfizer | 48 | $7,904 |
| Janssen Scientific Affairs, LLC | 12 | $4,530 |
| Dendreon Pharmaceuticals LLC | 24 | $1,138 |
| Novartis | 10 | $1,119 |
| Bayer | 31 | $839 |
| Johnson & Johnson | 40 | $833 |
| Astellas Pharma US Inc | 35 | $712 |
| Ferring Pharmaceuticals Inc. | 23 | $689 |
| AbbVie(2 entities) | 31 | $635 |
| Sumitomo Pharma America, Inc. | 40 | $518 |
| Teleflex LLC | 15 | $516 |
| Merck | 24 | $453 |
| Axonics, Inc. | 8 | $449 |
| Immunitybio, Inc. | 7 | $347 |
| Tolmar, Inc. | 18 | $334 |
| Boston Scientific | 6 | $296 |
| Urogen Pharma, Inc. | 16 | $294 |
| Myriad Genetic Laboratories, Inc. | 15 | $257 |
| AstraZeneca | 13 | $216 |
| Telix Pharmaceuticals | 8 | $146 |
| Verity Pharmaceuticals Inc. | 7 | $131 |
| Intuitive Surgical | 1 | $128 |
| Neotract Inc. | 1 | $99 |
| Progenics Pharmaceuticals, Inc. | 4 | $89 |
| Blue Earth Diagnostics | 4 | $73 |
| Tolmar Pharmaceuticals, Inc. | 3 | $62 |
| Amgen | 3 | $57 |
| Myovant Sciences Inc. | 3 | $52 |
| Dentsply IH AB | 1 | $37 |
| Ambu Inc. | 1 | $35 |
| Clinigen, Inc. | 2 | $31 |
| Coloplast | 2 | $31 |
| Clarus Therapeutics Inc. | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Procept Biorobotics Corporation | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Dentsply IH Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $12 |
| Urovant Sciences Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$2,071
- PROVENGE$558
- Axonics$313
- ADSTILADRIN$285
- ANKTIVA$256
- LithoVue$233
- Nubeqa$150
- PADCEV$145
- Da Vinci Surgical System$128
- UroLift System$127
- Xofigo$115
- UroLift$104
How this compares
$31,547 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 95 | $254,162 |
| ErleadaApalutamide | 13 | $194,130 |
| MyrbetriqMirabegron | 65 | $29,778 |
| Abiraterone Acetate | 29 | $26,936 |
| Tamsulosin Hcl | 586 | $11,193 |
| GemtesaVibegron | 12 | $9,634 |
| Finasteride | 154 | $2,855 |
| Silodosin | 15 | $1,584 |
| Tadalafil | 20 | $888 |
| Dutasteride | 18 | $863 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $574 |
| Oxybutynin Chloride ErOxybutynin Chloride | 29 | $540 |
| Testosterone | 11 | $251 |
| Levofloxacin | 122 | $235 |
| Prednisone | 27 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $518 | $263,796107 claims |
| Johnson & JohnsonErleada | $833 | $194,13013 claims |
| Astellas Pharma US IncMyrbetriq | $712 | $29,77865 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,530 | $26,93629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.
Other urology in Media
- George DakwarMedia$60K
- Laurence BelkoffBala Cynwyd$18.7M
- Paul SieberLancaster$12.6M
- Costas LallasPhiladelphia$3.6M
- John AndersonBethlehem$2.1M
- Jodi MaranchiePittsburgh$1.2M
- Kenneth LessansLancaster$943K
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.